Rajasree Pia Chowdry, MD | |
1542 Tulane Ave, Rm 442 Mail Box T4m-2, New Orleans, LA 70112-2865 | |
(504) 568-2127 | |
Not Available |
Full Name | Rajasree Pia Chowdry |
---|---|
Gender | Female |
Speciality | Hematology/oncology |
Experience | 14 Years |
Location | 1542 Tulane Ave, New Orleans, Louisiana |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013234079 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | 206160 (Louisiana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Medical Center New Orleans | New orleans, LA | Hospital |
Lallie Kemp Medical Center | Independence, LA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Lallie Kemp Medical Ctr | 0345238903 | 37 |
Louisiana State University School Of Medicine In New Orleans Faculty G | 0244136448 | 380 |
News Archive
The University of Manchester has entered into a new partnership with the US Food and Drug Administration to train new researchers and make advances in drug safety, development and personalised dosage.
The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain. Making such a universal influenza vaccine is feasible but licensing it may require innovation on several fronts, including finding new ways to evaluate the efficacy of vaccine candidates in clinical trials, conclude scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE's SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.
One of the biggest problems in the current treatment of cancer is that the agents that are efficacious in the destruction of tumorous cells are, at the same time, extremely toxic for the rest of the healthy cells and tissues of the patient.
› Verified 2 days ago
Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
The University of Manchester has entered into a new partnership with the US Food and Drug Administration to train new researchers and make advances in drug safety, development and personalised dosage.
The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain. Making such a universal influenza vaccine is feasible but licensing it may require innovation on several fronts, including finding new ways to evaluate the efficacy of vaccine candidates in clinical trials, conclude scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE's SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.
One of the biggest problems in the current treatment of cancer is that the agents that are efficacious in the destruction of tumorous cells are, at the same time, extremely toxic for the rest of the healthy cells and tissues of the patient.
› Verified 2 days ago
Entity Name | Lallie Kemp Medical Ctr |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1558303420 PECOS PAC ID: 0345238903 Enrollment ID: O20040503001188 |
News Archive
The University of Manchester has entered into a new partnership with the US Food and Drug Administration to train new researchers and make advances in drug safety, development and personalised dosage.
The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain. Making such a universal influenza vaccine is feasible but licensing it may require innovation on several fronts, including finding new ways to evaluate the efficacy of vaccine candidates in clinical trials, conclude scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE's SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.
One of the biggest problems in the current treatment of cancer is that the agents that are efficacious in the destruction of tumorous cells are, at the same time, extremely toxic for the rest of the healthy cells and tissues of the patient.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Rajasree Pia Chowdry, MD 27 Hunter Pl, Metairie, LA 70001-6159 Ph: (202) 316-0170 | Rajasree Pia Chowdry, MD 1542 Tulane Ave, Rm 442 Mail Box T4m-2, New Orleans, LA 70112-2865 Ph: (504) 568-2127 |
News Archive
The University of Manchester has entered into a new partnership with the US Food and Drug Administration to train new researchers and make advances in drug safety, development and personalised dosage.
The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain. Making such a universal influenza vaccine is feasible but licensing it may require innovation on several fronts, including finding new ways to evaluate the efficacy of vaccine candidates in clinical trials, conclude scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE's SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.
One of the biggest problems in the current treatment of cancer is that the agents that are efficacious in the destruction of tumorous cells are, at the same time, extremely toxic for the rest of the healthy cells and tissues of the patient.
› Verified 2 days ago
Leigh Victoria Deshotels, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave # Sl50, New Orleans, LA 70112 Phone: -- | |
Dr. James Desporte Lilly, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2820 Napoleon Ave, Suite 720, New Orleans, LA 70115 Phone: 504-896-8670 Fax: 504-896-8699 | |
Carmen Gladys Espinoza, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1542 Tulane Ave, New Orleans, LA 70112 Phone: 504-903-1301 | |
Jose Rodrigo Restrepo, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Department Of Radiology, 1542 Tulane Ave, Box T2-2, New Orleans, LA 70112 Phone: 504-568-4646 | |
Jorge Alan Martinez, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2021 Perdido St, New Orleans, LA 70112 Phone: 504-903-3000 | |
Dr. Princess Eronmwon Dennar, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave, Sl-16, New Orleans, LA 70112 Phone: 504-988-7518 Fax: 504-988-8252 | |
Eric Edward Holt I, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4747 Earhart Blvd Ste. J, New Orleans, LA 70125 Phone: 504-592-9818 Fax: 504-522-2248 |